🚀 VC round data is live in beta, check it out!
Rapport Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Rapport Therapeutics and similar public comparables like Youcare Pharmaceutical, Capricor Therapeutics, Concord Biotech, MBX Biosciences and more.
Rapport Therapeutics Overview
About Rapport Therapeutics
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Founded
2022
HQ
Employees
69
Website
Sectors
Financials (LTM)
EV
$882M
Rapport Therapeutics Financials
Rapport Therapeutics reported last 12-month revenue of $3M and negative EBITDA of ($138M).
In the same LTM period, Rapport Therapeutics generated ($138M) in EBITDA losses and had net loss of ($122M).
Revenue (LTM)
Rapport Therapeutics P&L
In the most recent fiscal year, Rapport Therapeutics reported revenue of — and EBITDA of ($82M).
Rapport Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | — | XXX | XXX | XXX |
| EBITDA | ($138M) | XXX | ($82M) | XXX | XXX | XXX |
| EBITDA Margin | (5085%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (4918%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($122M) | XXX | ($78M) | XXX | XXX | XXX |
| Net Margin | (4501%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Rapport Therapeutics Stock Performance
Rapport Therapeutics has current market cap of $1B, and enterprise value of $882M.
Market Cap Evolution
Rapport Therapeutics' stock price is $29.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $882M | $1B | 0.0% | XXX | XXX | XXX | $-1.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRapport Therapeutics Valuation Multiples
Rapport Therapeutics trades at 326.2x EV/Revenue multiple, and (6.4x) EV/EBITDA.
Rapport Therapeutics Financial Valuation Multiples
As of March 21, 2026, Rapport Therapeutics has market cap of $1B and EV of $882M.
Equity research analysts estimate Rapport Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rapport Therapeutics has a P/E ratio of (11.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $882M | XXX | $882M | XXX | XXX | XXX |
| EV/Revenue | 326.2x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (6.4x) | XXX | (10.7x) | XXX | XXX | XXX |
| EV/EBIT | (6.6x) | XXX | (10.6x) | XXX | XXX | XXX |
| P/E | (11.4x) | XXX | (17.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (13.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Rapport Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Rapport Therapeutics Margins & Growth Rates
Rapport Therapeutics' revenue in the last 12 month grew by 262%.
Rapport Therapeutics' revenue per employee in the last FY averaged $0.0M.
Rapport Therapeutics' rule of 40 is (4823%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rapport Therapeutics' rule of X is (4430%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Rapport Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 262% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (5085%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | 51% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (4823%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (4430%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1188% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3820% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Rapport Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Youcare Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Capricor Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Concord Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| MBX Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Caplin Point Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rapport Therapeutics M&A Activity
Rapport Therapeutics acquired XXX companies to date.
Last acquisition by Rapport Therapeutics was on XXXXXXXX, XXXXX. Rapport Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Rapport Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRapport Therapeutics Investment Activity
Rapport Therapeutics invested in XXX companies to date.
Rapport Therapeutics made its latest investment on XXXXXXXX, XXXXX. Rapport Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Rapport Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Rapport Therapeutics
| When was Rapport Therapeutics founded? | Rapport Therapeutics was founded in 2022. |
| Where is Rapport Therapeutics headquartered? | Rapport Therapeutics is headquartered in United States. |
| How many employees does Rapport Therapeutics have? | As of today, Rapport Therapeutics has over 69 employees. |
| Who is the CEO of Rapport Therapeutics? | Rapport Therapeutics' CEO is Abraham N. Ceesay. |
| Is Rapport Therapeutics publicly listed? | Yes, Rapport Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Rapport Therapeutics? | Rapport Therapeutics trades under RAPP ticker. |
| When did Rapport Therapeutics go public? | Rapport Therapeutics went public in 2024. |
| Who are competitors of Rapport Therapeutics? | Rapport Therapeutics main competitors are Youcare Pharmaceutical, Capricor Therapeutics, Concord Biotech, MBX Biosciences. |
| What is the current market cap of Rapport Therapeutics? | Rapport Therapeutics' current market cap is $1B. |
| What is the current revenue of Rapport Therapeutics? | Rapport Therapeutics' last 12 months revenue is $3M. |
| What is the current revenue growth of Rapport Therapeutics? | Rapport Therapeutics revenue growth (NTM/LTM) is 262%. |
| What is the current EV/Revenue multiple of Rapport Therapeutics? | Current revenue multiple of Rapport Therapeutics is 326.2x. |
| Is Rapport Therapeutics profitable? | No, Rapport Therapeutics is not profitable. |
| What is the current EBITDA of Rapport Therapeutics? | Rapport Therapeutics has negative EBITDA and is not profitable. |
| What is Rapport Therapeutics' EBITDA margin? | Rapport Therapeutics' last 12 months EBITDA margin is (5085%). |
| What is the current EV/EBITDA multiple of Rapport Therapeutics? | Current EBITDA multiple of Rapport Therapeutics is (6.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.